Monday, July 6, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
CRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and RobinhoodtodayENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting PaidtodayCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public NamestodayCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Opens a Multi-Billion Dollar Market for Novo and LillytodayENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense TradetodayENERGYThe HALEU Contract Nobody Prices In4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironmenttodayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR TherapeuticstodayENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear BeneficiariesyesterdayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger MarketyesterdayCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironmentyesterdayENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label SuppliersyesterdayCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout TradeyesterdayENERGYWho Gets Exposed When the SPR Refill Never Happens4 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin StoryyesterdayENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.4 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payer2 days agoENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model4 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiary2 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance4 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling It2 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.4 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Win2 days agoTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware4 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stocks2 days agoTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge4 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spot2 days agoENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog4 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immune2 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Means2 days agoENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivals3 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expense3 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers3 days agoENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risk3 days agoENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stack3 days agoTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind4 days agoDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving4 days agoTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech4 days agoDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid4 days agoDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market4 days agoENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom4 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money4 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat3 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever4 days agoENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom3 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock5 days agoDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch3 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch5 days agoDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes3 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers5 days agoDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization3 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political5 days agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear3 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending5 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch3 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game5 days agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop3 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk6 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade3 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade6 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Betlast weekDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTXlast weekENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligationlast weekENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Streamlast weekDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI2 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sideslast weekENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive2 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own Itlast weekDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime2 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machinelast weekDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending2 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Orderlast weekENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub2 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Programlast weekDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington2 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primeslast weekENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics2 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction2 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet2 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekENERGYThe BLM Calendar That Moves COP and OXYlast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast week
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

Medicare Covering Obesity Drugs for the First Time Opens a Multi-Billion Dollar Market for Novo and Lilly

Federal coverage of GLP-1s for Medicare beneficiaries is the single biggest demand catalyst the obesity-drug market has seen — and two companies hold most of the supply.

Image: Money Racket
By at Money Racket · Jul 6, 2026

Medicare will begin covering obesity drugs — specifically GLP-1 receptor agonists — for the first time, according to multiple reports. The change extends coverage to tens of millions of Medicare beneficiaries who were previously excluded from coverage for weight-loss medications, representing a structural demand expansion rather than a one-time event.

Who cashes in: Novo Nordisk (NVO) is the most direct beneficiary. Its semaglutide franchise — Ozempic for diabetes, Wegovy for obesity — is the market leader, and Medicare coverage removes the single biggest access barrier for its highest-growth product. One analyst estimate cited by Yahoo Finance suggests NVO may be trading at a 48% discount to fair value once Medicare volumes are priced in. Eli Lilly (LLY) is the other primary winner: its tirzepatide drugs (Mounjaro, Zepbound) compete directly and would see the same coverage-driven volume surge. Both are large-caps, so the move is meaningful but not explosive — the market has been pricing in some probability of this outcome for months.

Medicare coverage removes the single biggest access barrier for Wegovy and Zepbound — but the bill lands on Medicare Advantage insurers.

Who's exposed: Medicare Advantage insurers — UnitedHealth (UNH), Humana (HUM), and CVS Health (CVS) through its Aetna unit — face the cost side of this equation. GLP-1s run $800–$1,000 per month at list price. Even with rebates, mandatory coverage of these drugs across a large beneficiary population is a significant medical-loss ratio headwind unless CMS sets reimbursement rates that adequately reflect negotiated prices.

What to watch next: The CMS reimbursement rate announcement and whether Part D plan sponsors can negotiate meaningful rebates. The spread between list price and net price will determine whether this is a margin story for pharma or a cost story for insurers.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →